BF2.649 add on Modafinil

Phase 3Small molecule

BBioprojet

BF2.649 add on Modafinil is one of 4 small molecule programs targeting Cataplexy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CataplexyActive, not recruiting

CataplexyPhase 3

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Cataplexy

#DrugCompanyPhaseTrials

Wakix

HHarmony Biosciences Management, Inc.

Phase 3

2 2

BF2.649

BBioprojet

Phase 3

1 3

BF2.649 add on Modafinil

BBioprojet

Phase 3

1 4

Xyrem

Jazz Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cataplexy1 trial

Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy

Completed·BBioprojet·Phase 3·NCT01067235·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BF2.649 add on Modafinil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BF2.649 add on Modafinil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BF2.649 add on Modafinil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bioprojet company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBioprojet

BF2.649 add on Modafinil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cataplexy1 trial

References

Drug Info

Quick Facts

Related News